series-a
Stage
1
Investors
About
Palatin Technologies discovers and develops novel therapeutics targeting the melanocortin receptor system for treating obesity, including rare neuroendocrine diseases, as well as inflammatory and autoimmune conditions.
Explore Palatin Technologies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.